Gotham Asset Management LLC Purchases 2,485 Shares of Insulet Co. (NASDAQ:PODD)

Gotham Asset Management LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 57.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,827 shares of the medical instruments supplier's stock after purchasing an additional 2,485 shares during the period. Gotham Asset Management LLC's holdings in Insulet were worth $1,782,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank bought a new stake in shares of Insulet during the fourth quarter valued at approximately $248,806,000. Raymond James Financial Inc. purchased a new position in Insulet during the fourth quarter valued at $69,433,000. Alecta Tjanstepension Omsesidigt bought a new stake in shares of Insulet during the 4th quarter valued at $53,184,000. Artisan Partners Limited Partnership grew its position in shares of Insulet by 24.1% in the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Insulet by 20.5% in the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock worth $192,881,000 after acquiring an additional 125,710 shares in the last quarter.

Analysts Set New Price Targets

PODD has been the topic of a number of recent research reports. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a report on Tuesday, May 13th. Piper Sandler raised their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Barclays increased their target price on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target for the company. Finally, Canaccord Genuity Group upped their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $306.53.

Insulet Stock Performance

NASDAQ PODD traded up $1.63 during trading hours on Tuesday, hitting $327.47. 998,435 shares of the company's stock traded hands, compared to its average volume of 707,581. Insulet Co. has a 52 week low of $170.67 and a 52 week high of $328.84. The firm has a market capitalization of $23.05 billion, a P/E ratio of 56.56, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The business's fifty day moving average price is $265.69 and its two-hundred day moving average price is $267.57.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Insulet's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the firm earned $0.73 EPS. Equities research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity

In other Insulet news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.